Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 457-466

  Sims, Michael W ^a   Panettieri, Reynold A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aclidinium bromide; Bronchodilators; Chronic obstructive; Muscarinic antagonists; Pharmacokinetics; Pharmacology; Pulmonary disease

Indexed keywords

ACLIDINIUM BROMIDE; IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; (3R) 3 ((HYDROXY(DI 2 THIENYL)ACETYL)OXY) 1 (3 PHENOXYPROPYL) 1 AZONIABICYCLO(2.2.2)OCTANE BROMIDE; (3R)-3-((HYDROXY(DI-2-THIENYL)ACETYL)OXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO(2.2.2)OCTANE BROMIDE; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

ARTHRALGIA; ARTICLE; BINDING AFFINITY; BLURRED VISION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSED ANGLE GLAUCOMA; CONSTIPATION; COUGHING; DIARRHEA; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HEART INFARCTION; HUMAN; INFECTION; METERED DOSE INHALER; MYALGIA; NONHUMAN; POWDER INHALER; SINGLE DRUG DOSE; SORE THROAT; TACHYCARDIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; XEROSTOMIA; ANIMAL; DRUG EFFECT; EVIDENCE BASED MEDICINE; LUNG; PATHOPHYSIOLOGY; REVIEW; TIME;

ANIMALS; BRONCHODILATOR AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS; TREATMENT OUTCOME; TROPANES;

EID: 84856616976     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S15524     Document Type: Article

References (53)

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: Error! Hyperlink reference not valid. Accessed September 1, 2011.
2. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653.
3. Butler J, Caro CG, Alcala R, Dubois AB. Physiological factors affecting airway resistance in normal subjects and in patients with obstructive respiratory disease. J Clin Invest. 1960;39:584-591.
4. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989;96(5):984-987.
5. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 12A:24S-32S.
6. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122(1):47-55.
7. Rennard SI, Serby C W, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996;110(1):62-70.
8. van Koppen CJ, Blankesteijn WM, Klaassen AB, Rodrigues de Miranda J F, Beld AJ, van Ginneken CA. Autoradiographic visualization of muscarinic receptors in pulmonary nerves and ganglia. Neurosci Lett. 1987;83(3):237-240.
9. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):297-304.
10. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med. 1984;311(7): 421-425.
11. Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000; 117(2 Suppl):63S-66S.
12. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-1450.
13. Tashkin D P, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15): 1543-1554.
14. Tiotropium bromide inhalation solution [package insert]. 2010. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdf. Accessed June 29, 2011.
15. Turck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol. 2004;44(2):163-172.
16. Prat M, Fernandez D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicy clo[2.2.2]octane bromide (aclidinium bromide). J Med Chem. 2009;52(16):5076-5092.
17. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological Profile. J Pharmacol Exp Ther. 2009;331(2):740-751.
18. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330(2):660-668.
19. Cortijo J, Sarria B, Gavalda A, Miralpeix M, Morcillo E. In vitro characterization of aclidinium bromide, a novel long-acting anticholinergic: effects on isolated human bronchi [Abstract]. Proc Am Thorac Soc. 2008;5:A654.
20. Newman S P, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78(3):322-328.
21. Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory fow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103(12):1832-1837.
22. Al-Showair RA, Tarsin W Y, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation fow with all inhalers and does training help? Respir Med. 2007;101(11): 2395-2401.
23. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory fow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78-83.
24. de Koning J P, van der Mark T W, Coenegracht PM, Tromp TF, Frijlink H W. Effect of an external resistance to airfow on the inspira-tory fow curve. Int J Pharm. 2002;234(1-2):257-266.
25. Brand P, Meyer T, Weuthen T, et al. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007;47(10):1335-1341.
26. Johnson MA, Newman S P, Bloom R, Talaee N, Clarke S W. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Effcacy and pulmonary deposition. Chest. 1989; 96(1):6-10.
27. Howarth PH. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med. 2001;14 Suppl 1: S27-S34.
28. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010;39(5):283-290.
29. Alberti J, Martinet A, Sentellas S, Salva M. Identifcation of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos. 2010;38(7):1202-1210.
30. Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther. 2010;32(10):1798-1812.
31. Ipratropium bromide HFA inhalation solution [package insert]. 2010. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Atrovent+HFA/10003001_US_1.pdf. Accessed June 30, 2011.
32. Lasseter KC, Aubets J, Chuecos F, Gil EG. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol. 2011;51(6):923-932.
33. Schelfhout VJ, Ferrer P, Jansat JM, et al. Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. Br J Clin Pharmacol. 2010;69(5):458-464.
34. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010;23(1):15-21.
35. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol. 2009;49(10):1239-1246.
36. Jones PW, Rennard SI, Agusti A, et al. Effcacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011; 12:55.
37. Joos GF, Schelfhout VJ, Pauwels RA, et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010;104(6):865-872.
38. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinfation in patients with moderate to severe COPD. Respir Med. 2011;105(4):580-587.
39. Garcia Gil E, Ferrer P, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects [Abstract]. Eur Respir J. 2008;32 Suppl 52:642S.
40. Cortijo J, Mata M, Milara J, et al. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur Respir J. 2011;37(2):244-254.
41. Caramori G, Casolari P, Di Gregorio C, et al. MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology. 2009;55(3):321-331.
42. Innes AL, Woodruff PG, Ferrando RE, et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest. 2006;130(4):1102-1108.
43. Damera G, Jiang M, Zhao H, et al. Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway infammation. Eur J Pharmacol. 2010;649(1-3): 349-353.
44. Gwilt CR, Donnelly LE, Rogers D F. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary infammation? Pharmacol Ther. 2007;115(2):208-222.
45. Wessler IK, Kirkpatrick CJ. The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther. 2001;14(6): 423-434.
46. Profta M, Giorgi RD, Sala A, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic infammation in COPD patients. Allergy. 2005;60(11):1361-1369.
47. Maesen F P, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotro-pium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995;8(9): 1506-1513.
48. Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD. 2010;7(5):331-336.
49. Jones P W. St George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-79.
50. Casaburi R. Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD. 2005;2(1):131-136.
51. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168-1178.
52. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinfation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832-840.
53. O'Donnell DE, Sciurba F, Celli B, et al. Effect of futicasone propionate/salmeterol on lung hyperinfation and exercise endurance in COPD. Chest. 2006;130(3):647-656.